Profile data is unavailable for this security.
About the company
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
- Revenue in JPY (TTM)2.64bn
- Net income in JPY423.14m
- Incorporated1999
- Employees98.00
- LocationStemCell Institute IncMatsuoka Tamuracho Bldg.5-22-10, ShimbashiMINATO-KU 105-0001JapanJPN
- Phone+81 368113230
- Fax+81 368113240
- Websitehttps://www.stemcell.co.jp/
| Holder | Shares | % Held |
|---|---|---|
| Meiji Yasuda Asset Management Co. Ltd.as of 14 Aug 2023 | 187.90k | 1.83% |
| Nikko Asset Management Co., Ltd.as of 18 Jul 2023 | 127.00k | 1.24% |
| Simplex Asset Management Co., Ltd.as of 03 Oct 2024 | 52.20k | 0.51% |
| Deutsche Asset Management (Japan) Ltd.as of 10 Mar 2023 | 13.60k | 0.13% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 9.00k | 0.09% |
| Amundi Japan Ltd.as of 11 Sep 2023 | 800.00 | 0.01% |
| FIL Investments (Japan) Ltd.as of 15 Jul 2022 | 0.00 | 0.00% |
| SBI Okasan Asset Management Co. Ltd.as of 04 Mar 2024 | 0.00 | 0.00% |
| SBI Asset Management Co., Ltd.as of 22 Jun 2023 | 0.00 | 0.00% |
